Coordinating successful multi-regional inspections by FDA, PMDA and TFDA
Case study
Overview
The sponsor, an established biotech company with expertise in antibody drug conjugate development (ADC), partnered with ICON in 2020 for support with a phase 3 clinical trial. ICON provided clinical operation and regional oversight supports for the Asia Pacific (APAC) and Latin America (LATAM) regions, including Japan, South Korea, Singapore, Taiwan, Peru, Mexico, Argentina, and Brazil.
This was a complex multi-region oncology study assessing an investigational therapy for recurrent or metastatic cervical cancer in a late phase, registrational setting. Meticulous planning and close collaboration between ICON and the sponsor were essential requirements. During the program there were multiple regulatory inspections conducted by the FDA, PMDA and TFDA. ICON ensured that each global site was inspection-ready, compliant with GCP standards and that study conduct was consistent, regardless of site location.
Challenge
The FDA selected the study’s highest enrolling site in Japan, with 24 participants, for inspection. Both the PMDA and the TFDA selected sites for inspection. This was the first time to manage this combination of regulatory oversight, geography and scale within this program. Coordinating multiple site inspections across regions required seamless alignment between local and global teams to ensure that the pressure on timelines, resources and quality oversight did not impact the overall study. At the same time, it was crucial that sites were completely prepared with no detail overlooked. An inspection finding by any of the regulatory authorities could result in delayed regulatory approvals, derailing the sponsor’s global development strategy.
Solution
ICON leveraged its strength and resources as a global organisation with extensive experience in FDA and other regulatory agency inspections. To prepare for the inspections ICON deployed inspection-readiness tools across the sites, applying global knowledge to enable a structured preparation roadmap to support a successful inspection.
ICON identified inspection-related risks early and planned mitigation with the sponsor, strengthening trust and alignment. Early preparation and ICON’s knowledge of best practices ensured that the site was ready for the PMDA inspection. For the TFDA inspection, ICON’s experienced local team collaborated with the sponsor to execute the inspection activities efficiently. The ability to execute under pressure with excellence was a prerequisite to prepare for this complex convergence of inspections.
Outcome
All three inspections were successful with no findings, reflecting ICON’s strong inspection readiness and careful preparation of the sites. Cross-regional coordination between the APAC, LATAM and global teams and knowledge-sharing of best practices contributed to the successful outcome for the sponsor. This supported regulatory approvals in key markets including the US and Japan with no delays or risks to the development timeline. ICON’s proactive risk management, efficient and collaborative preparation led the sponsor to describe ICON as the best CRO they had worked with, reinforcing ICON’s position as a trusted global partner for late phase oncology development.